Medicare Drug Price Negotiation Initial Guidance: Comments due by April 14!

Medicare Drug Price Negotiation Initial Guidance: Comments due by April 14! On March 15, CMS issued initial guidance detailing the requirements and parameters—including requests for public comment—for the new Medicare Drug Negotiation Program for 2026, the first year the negotiated prices will apply.  CMS is committed to collaborating and engaging with the public in the implementation of the Inflation Reduction Act. We are working closely with patients and consumers, Medicare Part D plan sponsors and Medicare Advantage organizations, drug companies, hospitals and health care providers, wholesalers, pharmacies, and others.  Public feedback contributes to the success of the Medicare Drug Price Negotiation Program. The deadline for comments on the initial guidance is April 14, 2023. We hope that all types of stakeholders will contribute comments, which will be considered for revised guidance. CMS anticipates issuing revised guidance for the first year of negotiation in Summer 2023. Please send comments pertaining to this memorandum to IRARebateandNegotiation@cms.hhs.gov with the following subject line “Medicare Drug Price Negotiation Program Guidance.” Read the initial guidance. View CMS’ Drug Price Negotiation Timeline and a fact sheet on the initial guidance. Retweet from @Medicare to encourage others to comment. When CMS publishes the revised guidance for the Medicare Drug Price Negotiation Program this summer, CMS will communicate its rationale for revisions to the initial guidance in the revised guidance. In addition, CMS will make the comments submitted to CMS during the 30-day comment period for the initial guidance available on CMS.gov.